Lyophilized products are on the rise: Here's what you need to know

07.05.2021

There has been a steady increase in demand for lyophilized products in recent years. Due in large part to biologic drug innovation and technological advancement in the lyophilization process as well as ease of access to outsourcing partners who specialize in the formulation development and manufacturing of lyophilized biological products.

In this article, Emergent experts discuss the factors that are driving the demand of lyophilized products and what to consider when selecting a CDMO partner to support your drug manufacturing needs.

Emergent CDMO

Fill/Finish Thought Leadership

09.21.2020

Strategizing for Rapid Changeovers in Biologics Manufacturing

Syed T. Husain, senior vice president and CDMO business unit head at Emergent BioSolutions recently contributed to an editorial...

06.17.2020

Editorial: Good Manufacturing Practices: Challenges with Compliance

Dino Muzzin, Senior Vice President, Manufacturing Operations at Emergent, recently contributed to an article in BioPharm...

10.31.2020

Gene therapy solution: The value of a CDMO as your end-to-end partner

With ongoing advances in science and technology, the cell and gene therapy pipeline has grown especially robust over the past...